NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $213,420.60 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.

NewAmsterdam Pharma Stock Down 3.9 %

NewAmsterdam Pharma stock traded down $0.96 during trading hours on Tuesday, reaching $23.70. 507,785 shares of the company were exchanged, compared to its average volume of 275,345. NewAmsterdam Pharma has a 12 month low of $8.90 and a 12 month high of $26.35. The stock has a 50-day moving average of $18.68 and a 200 day moving average of $18.60.

Institutional Trading of NewAmsterdam Pharma

Large investors have recently modified their holdings of the company. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the second quarter valued at about $38,000. Quarry LP lifted its position in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new stake in NewAmsterdam Pharma in the 3rd quarter valued at approximately $128,000. Finally, XTX Topco Ltd bought a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $187,000. 89.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

NAMS has been the subject of several research reports. Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $33.80.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.